MEB-1170 Human Clinical Phase 1 Single Ascending Dose Outcomes

No Drug Related Adverse Events for MEB-1170 at All Doses Tested (20 mg to 400 mg)  

Safety Measures

    • Vitals: There were no notable trends in changes noted across the dose-range studied.

    • Blood chemistry: There were no notable trends in changes noted across the dose-range studied.

Respiratory Depression Measures

    • Saturated Oxygen: There were no notable trends of SpO2 changes noted across the dose-range studied.

    • Capnography: There were no notable trends of EtCO2 changes noted across the dose-range studied.

Pharmacokinetics

    • Achieved desirable exposures of MEB-1170 in humans

    • Dose linear exposures of MEB-1170. 

Cardiovascular Safety

    • No EKG abnormalities across the dose-range studied.

Sedation

    • None observed for MEB-1170 across the dose-range studied.